Skip to main content

and
  1. Article

    Open Access

    First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

    AOD01 is a novel, fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody that was developed as a therapeutic against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). This first-i...

    Venkateshan S. Prativadibhayankaram, Lawrence Soon-U Lee in Infectious Diseases and Therapy (2022)

  2. Article

    Open Access

    Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model

    COX-2 inhibition may be of benefit in the treatment of tuberculosis (TB) through a number of pathways including efflux pump inhibition (increasing intracellular TB drug levels) and diverse effects on inflammat...

    Claire M. Naftalin, Rupangi Verma, Meera Gurumurthy, Kim Hor Hee in Scientific Reports (2018)